Drug Profile
Remibrutinib - Novartis
Alternative Names: LOU-064; LOU064-NXA; NVP-LOU064-NXALatest Information Update: 01 Apr 2024
Price :
$50
*
At a glance
- Originator Novartis
- Class Amines; Anti-inflammatories; Antiallergics; Antiasthmatics; Benzamides; Cyclopropanes; Ethers; Fluorobenzenes; Pyrimidines; Skin disorder therapies; Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Chronic urticaria; Multiple sclerosis
- Phase II Hidradenitis suppurativa; Peanut hypersensitivity
- Discontinued Asthma; Atopic dermatitis; Sjogren's syndrome
Most Recent Events
- 23 Feb 2024 Efficacy and pharmacodynamics data from a phase II open-label extension trial in Chronic-urticaria presented at the 2024 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2024)
- 23 Feb 2024 Efficacy and pharmacodynamics data from a phase II trial in Chronic-urticaria presented at the 2024 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2024)
- 23 Feb 2024 Efficacy data from phase II trial in Chronic-urticaria presented at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2024)